EGFR and head and neck squamous cell carcinoma: (Xc–)-targeted therapy may also kill undifferentiated HNSCC cells expressing variant isoforms of CD44 (CD44v) and concurrently may sensitise the remaining HNSCC cells to available treatments including EGFR-targeted therapy165.